PCM
FENC icon

Prelude Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

Prelude Capital Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Hold
29,599
– – 0.02% 743
2026
Q1 		$182K Buy
+29,599
New +$229K 0.01% 934
2020
Q1 		– Sell
-244
Closed -$2K – 1600
2019
Q4 		$2K Sell
244
-26
-10% -$140 ﹤0.01% 1825
2019
Q3 		$1K Sell
270
-32
-11% -$141 ﹤0.01% 1635
2019
Q2 		$1K Sell
302
-13
-4% -$55 ﹤0.01% 1592
2019
Q1 		$2K Buy
+315
New +$2.07K ﹤0.01% 1678

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Prelude Capital Management's FENC Position: Q2 2026 in Review

Prelude Capital Management held its Fennec Pharmaceuticals (FENC) position steady in Q2 2026 at 29,599 shares worth $318K. The position accounts for 0.02% of the portfolio, ranked #743.

Prelude Capital Management first reported a position in FENC in Q1 2019 and has held it in 6 quarters since. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Prelude Capital Management held 29,599 shares of Fennec Pharmaceuticals worth $318K as of Q2 2026.
  • Prelude Capital Management left its Fennec Pharmaceuticals share count unchanged in Q2 2026.
  • Fennec Pharmaceuticals made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #743 holding.
  • Prelude Capital Management first reported a position in Fennec Pharmaceuticals in Q1 2019 and has held it in 6 quarters since.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.